Form 4: Lisata Therapeutics SVP Acquires Shares and Pays Taxes on Vesting Performance-Based Stock Units

James Nisco, SVP, Fin/Treas, Chief Actg Off of Lisata Therapeutics, reports acquisition of shares through performance-based stock units and withholding of shares for tax liability.

Summary

• On October 1, 2024, James Nisco, SVP, Fin/Treas, Chief Actg Off of Lisata Therapeutics, acquired 3,300 shares of common stock at $2.93 per share due to the vesting of performance-based stock units.
• On the same day, 1,701 shares were withheld to cover tax liabilities related to the vesting of these units, also at a price of $2.93.
• Following these transactions, Nisco directly owns 12,956 shares of Lisata Therapeutics common stock, which includes 9,482 unvested restricted stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it primarily reports transactions related to stock vesting and tax obligations, which are routine.

Positives

• The vesting of performance-based stock units suggests that performance criteria were met, which could be viewed positively.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, aligning with SEC regulations.
• Stock-based compensation is a common practice in the biotech industry to align management's interests with those of shareholders, similar to companies like Amgen, Gilead Sciences, and Biogen.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect changes in insider ownership.

Key Dates